- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: CTEP.
Displaying page 1 of 1.
EudraCT Number: 2018-004591-35 | Sponsor Protocol Number: ADVL1211 | Start Date*: 2018-12-14 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP) | ||
Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS | ||
Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-001576-13 | Sponsor Protocol Number: FJ-228-0002 | Start Date*: 2005-05-17 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA. | |||||||||||||
Medical condition: Metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000469-13 | Sponsor Protocol Number: FJ-228-0007 | Start Date*: 2006-03-10 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE | |||||||||||||
Medical condition: Refractory Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001238-32 | Sponsor Protocol Number: ADVL1622 | Start Date*: 2019-09-26 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation | ||
Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ||
Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-007147-28 | Sponsor Protocol Number: CLI-107-07 | Start Date*: 2008-02-29 | |||||||||||
Sponsor Name:CYTHERIS | |||||||||||||
Full Title: A PHASE I/IIa DOSE ESCALATION STUDY OF REPEATED ADMINISTRATION OF “CYT107” (glyco-r-hIL-7) ADD ON TREATMENT IN GENOTYPE 1 or 4 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIB... | |||||||||||||
Medical condition: Hepatitis C, genotypes 1 and 4 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001012-32 | Sponsor Protocol Number: GPI-04-0001 | Start Date*: 2005-03-31 |
Sponsor Name:Gloucester Pharmaceuticals Inc. | ||
Full Title: A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma | ||
Medical condition: Cutaneous T-cell lymphoma (CTCL), (peripheral T-cell lymphoma unspecified NOS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004950-10 | Sponsor Protocol Number: H3E-CR-S111 | Start Date*: 2008-01-28 | |||||||||||||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||||||||||||
Full Title: Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pe... | |||||||||||||||||||||||
Medical condition: Pacientes con cancer de pulmon no microcitico con enfermedad localmente avanzada o metastásica (estadios IIIA, IIIB o IV). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
